# Pfizer: Phase 1 study in Pancreatic Ductal Adenocarcinoma, Esophageal Cancer (280 participants)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Pfizer |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors. |
| NCT ID | NCT07903415 |
| Phase | Phase 1 |
| Status | recruiting |
| Conditions | Pancreatic Ductal Adenocarcinoma; Esophageal Cancer; Carcinoma, Non-Small-Cell Lung (NSCLC); Gastric Carcinoma; Gastroesophageal Junction Adenocarcinoma |
| Intervention types | drug |
| Target enrollment | 280 |
| Site countries | United States |
| Posted | 2026-10-29 |
| Planned start | 2026-10-29 |
| Event | Newly registered study |
| Event date | 2026-10-29 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- 280 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07903415). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.